SG11201807977XA - Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor - Google Patents

Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Info

Publication number
SG11201807977XA
SG11201807977XA SG11201807977XA SG11201807977XA SG11201807977XA SG 11201807977X A SG11201807977X A SG 11201807977XA SG 11201807977X A SG11201807977X A SG 11201807977XA SG 11201807977X A SG11201807977X A SG 11201807977XA SG 11201807977X A SG11201807977X A SG 11201807977XA
Authority
SG
Singapore
Prior art keywords
heidelberg
international
checkpoint inhibitor
cancer therapy
combined
Prior art date
Application number
SG11201807977XA
Other languages
English (en)
Inventor
Barbara Leuchs
Antonio Marchini
Jean Rommelaere
Assia Angelova
Dirk JÄGER
Wolfgang Wick
Michael Dahm
Original Assignee
Deutsches Krebsforsch
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls filed Critical Deutsches Krebsforsch
Publication of SG11201807977XA publication Critical patent/SG11201807977XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201807977XA 2016-04-01 2017-03-22 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor SG11201807977XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163555 2016-04-01
EP16020193.5A EP3225253A1 (en) 2016-04-01 2016-05-27 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
PCT/EP2017/056886 WO2017167626A1 (en) 2016-04-01 2017-03-22 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
SG11201807977XA true SG11201807977XA (en) 2018-10-30

Family

ID=55650316

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807977XA SG11201807977XA (en) 2016-04-01 2017-03-22 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Country Status (16)

Country Link
US (2) US11027013B2 (ko)
EP (1) EP3225253A1 (ko)
JP (1) JP6689400B2 (ko)
KR (1) KR102195055B1 (ko)
CN (1) CN109069601B (ko)
AU (1) AU2017242089B2 (ko)
BR (1) BR112018069927A2 (ko)
CA (1) CA3019634A1 (ko)
CL (1) CL2018002793A1 (ko)
EA (1) EA037354B1 (ko)
IL (1) IL261554B (ko)
LT (1) LT3436058T (ko)
MX (1) MX2018010709A (ko)
SG (1) SG11201807977XA (ko)
WO (1) WO2017167626A1 (ko)
ZA (1) ZA201805548B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170133A1 (en) * 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN109022616B (zh) * 2018-07-25 2021-11-12 广州烨善生物科技有限公司 一种检测溶瘤病毒的探针及其应用
EP3657172A1 (en) 2018-11-22 2020-05-27 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample
JP2022524921A (ja) * 2019-02-01 2022-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド がんを治療するための、ペムブロリズマブと組み合わせたベランタマブマフォドチン
AU2020228053A1 (en) * 2019-02-28 2021-09-23 Shattuck Labs, Inc. Combination therapies
CN111154806A (zh) * 2020-01-08 2020-05-15 深圳普菲科生命科技有限公司 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
US7179456B2 (en) * 2003-04-30 2007-02-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of parvovirus for brain tumor therapy
JP4361545B2 (ja) 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
EP2082745B1 (en) * 2007-12-28 2012-12-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Cancer therapy with a parvovirus combined with chemotherapy
AU2009213738B2 (en) 2008-02-11 2015-01-22 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2376535B9 (en) 2008-12-09 2017-09-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
EP2266587A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oncolytic virotherapy for prevention of tumor recurrence
EP2366398A1 (en) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
EP2397542A1 (en) 2010-06-17 2011-12-21 Deutsches Krebsforschungszentrum Modified parvovirus having enhanced anti-tumour efficacy
EP2404609A1 (en) * 2010-07-07 2012-01-11 Deutsches Krebsforschungszentrum Use of parvovirus for eliminating cancer stem cells (CSCs)
EP2535055A1 (en) * 2011-06-15 2012-12-19 Deutsches Krebsforschungszentrum Oncolytic virotherapy for therapy of bone cancer
US20130129678A1 (en) * 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
EP2829284A1 (en) * 2013-07-22 2015-01-28 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CN106456747A (zh) * 2014-05-13 2017-02-22 巴法里安诺迪克有限公司 用表达肿瘤抗原的重组痘病毒和免疫检查点分子拮抗剂或激动剂治疗癌症的组合疗法
CA2955084C (en) * 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
EP3108892A1 (en) * 2015-06-23 2016-12-28 Deutsches Krebsforschungszentrum Parvovirus formulation for treating tumors

Also Published As

Publication number Publication date
CA3019634A1 (en) 2017-10-05
JP6689400B2 (ja) 2020-04-28
KR102195055B1 (ko) 2020-12-24
IL261554A (en) 2018-10-31
LT3436058T (lt) 2020-02-10
US11027013B2 (en) 2021-06-08
NZ745264A (en) 2020-10-30
JP2019510769A (ja) 2019-04-18
ZA201805548B (en) 2019-11-27
CN109069601B (zh) 2022-05-10
EA037354B1 (ru) 2021-03-17
US11964015B2 (en) 2024-04-23
CL2018002793A1 (es) 2019-02-01
WO2017167626A1 (en) 2017-10-05
EA201891679A1 (ru) 2019-04-30
AU2017242089A1 (en) 2018-08-30
US20210228714A1 (en) 2021-07-29
US20190117768A1 (en) 2019-04-25
AU2017242089B2 (en) 2019-08-15
KR20180127468A (ko) 2018-11-28
BR112018069927A2 (pt) 2019-02-05
CN109069601A (zh) 2018-12-21
MX2018010709A (es) 2019-01-14
IL261554B (en) 2022-05-01
EP3225253A1 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
SG11201807977XA (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
SG11201908547VA (en) Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
SG11201811432WA (en) Rna for cancer therapy
SG11201806340YA (en) Zika virus vaccine
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201805120YA (en) Zika virus vaccine
SG11201408261UA (en) Syringe
SG11201807912SA (en) Vaccine against rsv
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201407200TA (en) Liquid formulation
SG11201407961WA (en) Risperidone or paliperidone implant formulation
SG11201909520VA (en) Rna for treatment of autoimmune diseases
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201406987UA (en) Glucokinase activator compositions for the treatment of diabetes